Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Oncology Center of Excellence

Oncology Center of Excellence

                        Who We Are - Oncology Center of Excellence
          Project Patient Voice


                        OCE Annual Reports
          Project Community Home
          About FDA
          FDA Organization
          Oncology Center of Excellence
          About Oncology Prescription Drug LabelingOncology Center of Excellence About Oncology Prescription Drug Labeling
  
  	
    Share
    Post
    Linkedin

    Email
    PrintJump to:

What is Prescription Drug Labeling?
	How is Prescription Drug Labeling Approved?
	How is Product Labeling Updated?

What is Prescription Drug Labeling?

Prescription drug labeling [e.g., U.S. Prescribing Information (USPI)] contains a summary of the essential scientific information needed for the safe and effective use of the drug. The USPI provides healthcare providers who use oncology prescription drugs unbiased information regarding the use of the drug, including the setting in which the drug has been shown to be safe and effective, recommended dose and schedule, recommended modifications for toxicity, in patients with renal or hepatic impairment, or based on drug interactions, as well as a summary of potential side effects including severity and frequency.

Additionally, when approved, the USPI is an unbiased source of summary information submitted by the drug manufacturer and then comprehensively reviewed at the FDA for clinical studies conducted to establish the safety and effectiveness of the drug. While many different sources of drug information exist, the USPI provides strong assurances of scientific accuracy.



How is Prescription Drug Labeling Approved?

The oncology product labeling review process is a data-driven, collaborative process conducted by multidisciplinary FDA teams.

Prescription Drug Labeling
Number 1

Company Submits Draft USPI

A drug company submits a marketing application containing the data supporting the safety and effectiveness of their oncology drug based on one or more clinical studies. The marketing application may be a New Drug Application (NDA), Biologic License Application (BLA), or a supplement to one of these applications. The application must include their proposed USPI.

Number-2

FDA Forms Application Review Team

An FDA review team typically includes physicians, pharmacologists, toxicologists, statisticians, pharmacists, chemists/biologists, safety specialists, and regulatory scientists.

Consultative reviewers are assigned to evaluate for promotional content and the potential for medication errors in the USPI and to review patient labeling. Additional consultative reviewers with specific subject matter expertise are often added to the review team based on the oncology drug’s proposed conditions of use (e.g., pediatricians, patient reported outcome specialists, epidemiologists, maternal health specialists, pharmacogenomic specialists, and/or other specialists). Furthermore, if the prescription oncology drug must be used with a device (i.e, in vitro diagnostic device, autoinjector), engineers evaluate these devices.

Number-3

FDA Review of Submission

The FDA review team evaluates the data submitted by the company to determine their adequacy to support approval or new claims and may ask the company for additional data or to clarify certain findings.

If data are adequate, the USPI undergoes a comprehensive review to ensure that the USPI is scientifically accurate, concise and clear, meets regulatory/statutory requirements, and is consistent with FDA guidances for USPI and patient labeling content and format.

Number-4

Final Approved USPI

The final approved USPI is developed in agreement between the FDA and the company.



How is Product Labeling Updated?

Maintaining FDA-approved USPI occurs throughout the drug’s lifecycle. After initial approval, companies are required to update their USPI when new information becomes available that causes the USPI to be inaccurate, false, or misleading. Additionally, FDA may ask the company to update their labeling by issuing a supplement request letter. This action is most often taken based on identification of new postmarketing safety signals identified by FDA surveillance to conform to new labeling requirements/guidance; or identification of new scientific evidence related to the drug class that is important to the safe and effective use of the drug.

Additional Information

Project Renewal Home
	Project Renewal FAQ
	About Product Labeling
	FDA Oncology Center of Excellence Home
	Prescription Drug Labeling Resources

                                                                                  Content current as of:
      06/23/2020Oncology Center of Excellence

          
                        Who We Are - Oncology Center of Excellence
          Project Patient Voice


                        OCE Annual Reports
          Project Community
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop